NASDAQ : LIMN

Liminatus Pharma, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 2.82 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.79M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.

Details

NameLiminatus Pharma, Inc.
SectorHealthcare
IndustryBiotechnology
Employees1
Founded2018
CeoChris Kim
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS53271X2071
Cusip53271X207
Cik0001971387
Sic2836
Stock TypeCommon Stock

Key executives

NameTitle
Chris Kim J.D., L.L.M.Chief Executive Officer, Chairman and President
Scott DamChief Financial Officer
Dr. Beom Kyu ChoiChief Technology Officer and Member of Scientific Advisory Board
Dr. Byong Chul Yoo Ph.D.Chief Science Officer and Member of Scientific Advisory Board

Contact

Address12611 Hiddencreek Way, Unit C, Cerritos, California 90703, United States
Phone213 273 5453
Websitehttps://liminatuspharma.com